$VICR

Davies Philip D sold $160K of VICR

Davies Philip D (VP Global Sales & Marketing) sold 500 shares of VICOR CORP (VICR) at $319.02 ($0.16M total) on 2026-06-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Davies Philip D
Published Jun 2, 2026, 2:11 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 2, 2026, 2:15 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$VICR
Neutral
medium confidence
Mentioned
$VICR
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$VICRNeutralLow
01

Why it matters

This provides a datapoint on insider behavior but does not change VICR’s fundamentals or guidance in the article.

02

Market read

Use as a sentiment/positioning check rather than a catalyst; expect limited trading impact absent additional corroborating news.

03

What to watch

Insider selling can still reflect liquidity needs or diversification rather than bearish fundamentals; the filing size ($159.5k) is relatively small versus typical institutional flows.

Relevance 6/10Novelty 3/10Timing: filed today; sale occurred 2026-06-01

Background

The article is an SEC Form 4 insider transaction disclosure for VICOR (VICR), indicating an officer/director sale executed under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$VICRNeutralMedium confidence
Context

SEC Form 4 shows VP Global Sales & Marketing Philip D. Davies sold 500 shares of VICOR at ~$319.02 via an open-market transaction under a 10b5-1 plan.

Expected impact

Likely limited near-term impact; treat as routine insider activity unless follow-on filings show unusual acceleration or larger size.

Evidence & confidence

The filing is an ownership-change disclosure with a stated pre-arranged 10b5-1 plan, which typically dampens market interpretation and does not introduce new company fundamentals.

Market effects

Minimal; this is company-specific insider activity with no stated operational or regulatory catalyst.

None indicated.

None indicated.

Counterpoint

Because the sale is under a 10b5-1 plan, the market may overreact; price action could be muted or even positive if broader tape is strong.

Key entities

  • VICOR CORP

    Subject of the SEC Form 4 insider transaction disclosure.

  • Philip D. Davies

    VP Global Sales & Marketing; sold 500 shares under a 10b5-1 plan.

Related articles

$VICRMedAI 8/10

Vicor (VICR) Q2 2026 Earnings Call Transcript

Vicor’s Q2 2026 earnings call reported product and royalty revenue of $143.4M, up 26.9% sequentially and 1.6% year over year. Advanced products revenue rose to $94.2M. Net income was $49.8M, GAAP diluted EPS $1.40, and cash was $453.6M. The company guided for nearly 10% Q3 revenue growth and over $600M 2026 revenue, citing capacity increases and licensing assumptions.

$VICRMed

Vicor Corp (VICR) Q2 2026 Earnings Call Highlights: Strong Revenue Growth

Vicor Corp said a new license agreement will bring $5 million quarterly payments in year one and $10 million in year two, with $15 million contributing to Q2 revenue and additional revenue recognition expected in Q3 and subsequent quarters. Management also discussed fab capacity expansion to support a $2.5 billion revenue goal and said backlog growth stems mainly from existing customer demand.

$VICRMed

VICOR CORP (VICR): Results of Operations and Financial Condition

VICOR CORP (VICR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 d115827dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 NEWS RELEASE FINANCIAL NEWS BRIEF July 21, 2026 For Immediate Release Vicor Corporation Reports Results for the Second Quarter Ended June 30, 2026 Andover, Mass., July 21, 2026 (GLOBE NEWSWIRE) — Vicor Corporation (NASDAQ: